Kornimate/medical-research-clean huggingface dataset:
mk0653c in high cardiovascular risk patients with high cholesterol (switch study)(mk-0653c-162)

Conditions: Hypercholesterolemia

Summary: this study will compare the lipid-altering efficacy and safety of switching to co-administration of ezetimibe and atorvastatin versus treatment with atorvastatin or rosuvastatin in high cardiovascular risk patients with hypercholesterolemia who have not achieved specified low-density lipoprotein cholesterol (ldl-c) levels. the primary hypothesis is that the co-administration of ezetimibe 10 mg and atorvastatin 10 mg will be superior to both atorvastatin 20 mg and rosuvastatin 10 mg with respect to the percentage reduction in low-density lipoprotein-cholesterol (ldl-c) after 6 weeks of treatment.

this is a 18 week randomized, double-blind, active-controlled, multicenter study composed of a 6 week screening/run-in and 12 week double-blind treatment period (composed of 2 phases; each 6 weeks in duration). only those participants who do not meet low density lipoprotein-cholesterol (ldl-c) goals at the end of phase i (week 6), were eligible to continue into phase ii (week 12).

Eligibility criteria:
inclusion criteria: * patient is at high cardiovascular risk and meets one of the following conditions: has never taken lipid-lowering therapy or has been off such therapy for at least 6 weeks; or, is currently taking a stable dose of certain lipid-lowering agents * patient is willing to maintain a cholesterol lowering diet during the study * female patients receiving non-cyclical hormone therapy have maintained a stable dose and regimen for at least 8 weeks and are willing to continue the same regimen during the study exclusion criteria: * patient is asian * patient routinely has more than 2 alcoholic drinks per day * female patient is pregnant or breastfeeding * patient has congestive heart failure * patient has had a myocardial infarction, coronary bypass surgery, angioplasty, or acute coronary syndrome within 3 months of screening * patient has uncontrolled cardiac arrhythmias * patient has had a partial ileal or gastric bypass or other significant intestinal malabsorption * patient has uncontrolled high blood pressure * patient has kidney disease * patient has any disease known to influence blood lipid levels * patient has any disorders of the blood, digestive system, or nervous system including stroke and degenerative disease that would limit study participation * patient has poorly controlled or newly diagnosed diabetes * patient is known to be hiv positive * patient has a history of cancer in the last 5 years, except certain skin and cervical cancers
intensive lipid lowering treatment in non-st-elevation acute coronary syndrome (nste-acs) patients

Conditions: Acute Coronary Syndrome

Summary: pci has been one of the most common choice of treatments for patients with coronary artery disease, and studies indicated that intensive statin treatment before pci could reduce adverse events as comparing to the placebo. in china, statin with regular dose is currently applied to the patients admitted for non-st-elevation acute coronary syndrome (acs). here we hypothesize that intensive statin treatment with arovastatin before pci could further reduce clinical adverse events.


Eligibility criteria:
inclusion criteria: * finish informed consent * age≥18y and under 75y * diagnosed as non-st elevation acute coronary syndrome, including unstable angina and non-st elevation myocardial infarction * willing to receive the coronary angiography and potential pci therapy exclusion criteria: * patient was treated by statins before randomization * stable angina or st elevation myocardial infarction * without informed consent * abnormal liver function before randomization, (ast，alt≥3uln) * active hepatitis or muscular disease * impaired renal function with serum creatinine level \> 3mg/dl * impaired left ventricular systolic function with lvef\< 30% * participating in other studies * non-pci treated patients after coronary angiography will be washed out

Keywords: acute coronary syndrome intervention outcome patients diagnosed ad non-st elevation acs patients received pci therapy
dahanca 27 transoral laser microsurgery for t1a glottic cancer

Conditions: Head and Neck Squamous Cell Carcinoma; Glottic T1

Summary: to evaluate whether transoral laser microsurgery (tlm) is non-inferior compared to accelerated radiotherapy (accrt) in the treatment of t1an0m0 glottic scc

since 2003 the danish national standard treatment for t1an0m0 glottic scc has been accelerated rt (66gy. 2 gy/fraction, 6 fractions/week). in 2012 cordectomy type i-iii using tlm was introduced as an experimental treatment. the dahanca 27 trial is a comparative non-inferiority phase ii study comparing two timely separated national patient cohorts. patients treated with radical tlm from september 2012 to april 2016 were included in the tlm cohort, and patients treated with accelerated rt from january 2003 to august 2012 were included in the rt cohort

Eligibility criteria:
inclusion criteria: * danish patients aged ≥18 years diagnosed with a t1an0m0 glottic squamous cell carcinoma (scc) exclusion criteria: * unable to complete curative intended protocol treatment and/or planned follow up * informed concent

Keywords: transoral laser microsurgery accelerated radiotherapy
oral dexamethasone for treatment of migraine

Conditions: Migraine

Summary: the aim of this project is to determine if a single dose of oral dexamethasone at the time of discharge from the emergency department (ed) \[after successful treatment\] prevents rebound headache. hypothesis: that single dose oral dexamethasone 8mg reduces the proportion of patients who suffer rebound headache after treatment for migraine in the ed.

migraine headache can be a debilitating condition. a small but significant proportion of sufferers seek treatment in emergency departments \[ed\], accounting for 2-5% of ed visits.available data suggests that up to 66% of these patients may experience rebound headache after discharge that affects their ability to function normally \[eg work, social, etc\].it appears that inflammation plays a key role in recurrences. a number of small studies suggest that a single dose of corticosteroids at the time of discharge might prevent rebound headache. to date these studies have used intravenous dexamethasone. the aim of this project is to determine if a single dose of oral dexamethasone at the time of discharge from the ed \[after successful treatment\] prevents rebound headache. hypothesis: that single dose oral dexamethasone 8mg reduces the proportion of patients who suffer rebound headache after treatment for migraine in the ed. aims: the primary aim is to compare the proportion of patients who experience rebound headache within 48 hours after ed treatment of migraine between a group treated with single dose oral dexamethasone 8mg and a group treated with placebo. secondary aims are to compare headache severity, analgesia/ health service use, adverse events and return to normal functioning between the groups. methods: study design: double blind, randomised placebo controlled clinical trial. setting: emergency department, western hospital. participants: adult patients \[age \>17 years\] with physician-diagnosed migraine treated in the ed. inclusion criteria: consenting adult patients \[age \>17 years\] with physician-diagnosed migraine treated in the ed who are willing and able to be contacted between 48-72 hours after discharge for follow-up. sample size: 76 patients. note: the study was stopped early for operational reasons. 63 patients were analysed.

Eligibility criteria:
inclusion criteria: * consenting adult patients \[age \>17 years\] with physician-diagnosed migraine treated in the ed who are willing and able to be contacted between 48-72 hours after discharge for follow-up exclusion criteria: * failure to consent * pregnancy * allergy to study medication * findings inconsistent with migraine * patients requiring hospital admission for further investigation and treatment * patients with active peptic ulcer disease * patients with type 1 diabetes * patients taking corticosteroids for another condition within 7 days * active systemic fungal infection * patients previously enrolled in the study

Keywords: migraine headache rebound headache
obpm_coyote2024 physiological data recording with the calibration-free optical aktiia g2c device at fingertip and wrist, alongside the aktiia oscillometric cuff

Conditions: Hypertension

Summary: the present study, obpm_coyote2024, with n = 255 participants minimum over 1 visit (lasting \~15min), has been designed to collect raw optical data with aktiia.product-g2c clinical investigational device together with aktiia g2 bracelet and aktiia init i1 oscillometric cuff within a cohort of subjects characterized by a wide variety of phenotypes. the resulting dataset will support research and development activities conducted by aktiia sa out of the study context.


Eligibility criteria:
inclusion criteria: * subjects aged 21 to 85yo * subjects or witnesses fluent in written and spoken french * subjects agreeing to attend the study visit and follow study procedures * subjects that have signed the informed consent form. exclusion criteria: * amputated index fingers * damaged/injured skin at index fingers * damaged/injured skin at wrists * subjects with tachycardia (heart rate at rest \> 120bpm) * subjects with atrial fibrillation * subjects with diabetes * subjects with marked renal dysfunctions (egfr \< 30ml/min/1.73 m2) * subjects with untreated hyper-/hypothyroidism * subjects with pheochromocytoma * subjects with raynaud's disease * subjects with an arteriovenous fistula * women in known pregnancy * history of polyneuropathy

Keywords: hypertension blood pressure
observational retrospective study on treatment and outcomes in patients with low-grade serous ovarian cancer

Conditions: Low-grade Serous Ovarian Carcinoma; Recurrent Invasive Borderline Serous Ovarian Cancer

Summary: the purpose of this study is to retrospectively evaluate treatments and outcomes of patients with low grade serous ovarian carcinomas in italy.


Eligibility criteria:
inclusion criteria: * diagnosis low-grade serous ovarian carcinoma * or invasive recurrence after surgical resection of borderline serous ovarian carcinoma * availability of archival tumor specimen (paraffin embedded block) for central analysis and evaluation for mutations * age \> 18 years * signed informed consent exclusion criteria: * high-grade serous, mucinous, endometrioid, or any other non-low-grade serous ovarian carcinoma * unavailability of archival tumor specimen

Keywords: chemotherapy hormone therapy borderline low-grade serous ovarian cancer
clinical characteristics of allergy, autoimmune and rheumatic diseases: a ten year retrospective study

Conditions: Allergy; Autoimmune Diseases; Rheumatic Diseases

Summary: the incidence and prevalence of the allergic, autoimmune and rheumatic diseases are different all over the world. the relative impact of gene and environment on diseases can be revealed by studies from different populations. national health insurance database in taiwan provides a wealth of epidemiology study, which can contribute to the understanding of these diseases. however, national health care database did not contain test results and clinical details. the database of the hospital records can provide complimentary clinical details. via the comparison of databases of the national health institutes and the investigators hospital, the investigators hope that the characteristics and outcomes of these patients can be better understood.

the incidence and prevalence of the allergic, autoimmune and rheumatic diseases are different all over the world. the relative impact of gene and environment on diseases can be revealed by studies from different populations. national health insurance database in taiwan provides a wealth of epidemiology study, which can contribute to the understanding of these diseases. however, national health care database did not contain test results and clinical details. the database of the hospital records can provide complimentary clinical details. via the comparison of databases of the national health institutes and the investigators hospital, the investigators hope that the characteristics and outcomes of these patients can be better understood. briefly, epidemiology of target disease such as age, sex, incidence and prevalence will be derived from national database. medical source utilization such as medication and surgery related to target diseases is also available in national database, providing material for cost analysis. these data can be compared with hospital database to ensure validity and reliability. the investigators study is intended to provide epidemiology of target disease and cost analysis. interaction between diseases will also be explored. target diseases allergic diseases: asthma(icd9 493.x),steven-johnson syndrome and other erythroderma (icd9 695.x) autoimmune diseases: thyroid disease (icd9 246.x), addison disease (icd9 255.x), type 1 diabetes mellitus (250.x1) rheumatic diseases: gout (icd9 274.x), sle (icd9 710.0 ), ra (icd9 714.0), as and spondylitis (icd9 720.0\&720.x), psoriasis and psoriatic arthritis (icd9 696.0), scleroderma (icd9 710.1), sjogren's syndrome (icd9 710.2), dermatomyositis (icd9 710.3), polymyositis (icd9 710.4), anca vasculitis (wg 446.4, mpa, css, pan icd9 446.0) or vasculitis 447.6, behcet's disease(icd9 136.1), temporal arteritis(icd9 446.5), takayasu arteritis (icd9 446.7), henoch-schonlein purpura (icd9 287.0)

Eligibility criteria:
inclusion criteria: * subjects with icd9 coding fulfilling study subjects

Keywords: allergy autoimmune diseases rheumatic diseases
database evaluating outcomes of using carbetocin as the primary uterotonic following cesarean delivery

Conditions: Carbetocin; Cesarean Section Complications; Uterotonics; Uterine Atony With Hemorrhage

Summary: carbetocin (duratocin®) is a long-acting form of oxytocin, with a half-life almost 10 times longer. studies have demonstrated that carbetocin diminishes the need for secondary uterotonic agents compared to oxytocin for cesarean delivery (cd). despite certain canadian guidelines recommending its use for elective cd, several canadian centers and other countries have not adopted carbetocin. the purpose of this study is to prospectively gather electronic data on all cds over a one year period, elective and emergent, in a single institution, and to evaluate the efficacy and other clinical outcomes when carbetocin is used as a first line uterotonic for all cds. a database using microsoft dynamics crm is available on smart phones and tablets. data regarding additional uterotonic use and impact of carbetocin use during cd on intra and postoperative outcomes are gathered and analyzed. the primary outcome is the use of additional uterotonics in this population compared to that described in the literature for oxytocin as the primary uterotonic.


Eligibility criteria:
inclusion criteria: * all cesarean deliveries in the operating room. exclusion criteria: * vaginal deliveries and double set-up vaginal deliveries conducted in the operating room.
point-of-care ultrasound to assess hydronephrosis in patients with acute kidney injury in the emergency department

Conditions: Acute Kidney Injury; Urinary Tract Obstruction

Summary: acute kidney injury (aki) is a common diagnosis in the emergency department (ed), and urinary tract obstruction is a contributing cause that requires rapid diagnosis and therapeutic management. this observational study aims at assessing the accuracy of point-of-care ultrasound (pocus), performed by the emergency physician (ep) for the detection of dilatation or distension of the kidney secondary to urinary tract obstruction, in emergency department patients presenting with acute kidney injury (aki). participants will undergo a bedside pocus of the urinary tract by the ep followed by central imaging evaluation by a radiologist (either ultrasound or renal computed tomography (ct) or both). researchers will compare both diagnosis. study hypothesis is that trained emergency physicians can rapidly and reliably diagnose renal tract obstruction at pocus in the context of aki.

acute kidney injury (aki) is a common diagnosis in the emergency department (ed), and urinary tract obstruction is a contributing cause that requires rapid diagnosis and therapeutic management. hydronephrosis is a dilatation or distension of the kidney secondary to urinary tract obstruction. it can be diagnosed at ultrasonography or computed tomography. assessment of the renal tract and detection of hydronephrosis is a core component of the emergency medicine point-of-care ultrasound (pocus) curriculum. the primary objective of this study is to compare the performance of point-of-care ultrasound performed by the emergency physician to that of central radiology imaging (us or ct) by a radiologist, to diagnose hydronephrosis in patients presenting with aki in the ed. all imaging exams will be performed as part of routine evaluation, pocus will be carried out by a trained ep blinded from radiology imaging results.

Eligibility criteria:
inclusion criteria: * patient with acute kidney injury defined by changes in serum creatinine (scr) level between the index scr at ed admission and pre and/or post scr controls (kidney disease improving global outcome criteria) * patient who does not oppose to the use of their data exclusion criteria: * vesical globe * polycystic kidney disease * known renal tumor * horseshoe kidney

Keywords: point-of-care ultrasound acute kidney injury hydronephrosis urinary tract obstruction emergency medicine
assessment of wall thickness in hypertrophic cardiomyopathy

Conditions: Hypertrophic Cardiomyopathy

Summary: assessment of wall thickness in hypertrophic cardiomyopathy (hcm) is of diagnostic and prognostic importance given its known association with sudden cardiac death. however, data regarding comparison of imaging modalities for this key measurement is lacking. this study seeks to compare assessment of maximum wall thickness between clinically indicated echocardiography (with and without contrast) and clinically indicated cardiac magnetic resonance imaging.

patients receiving clinically indicated echocardiograms and cardiac magnetic resonance imaging at mayo clinic will be eligible.

Eligibility criteria:
inclusion criteria: 1. clinically and echocardiographically defined hypertrophic cardiomyopathy. 2. clinically indicated transthoracic echocardiography as part of the medical evaluation. 3. no contradiction to administration of ultrasonic echocardiography contrast. 4. planned clinically indicated cardiac magnetic resonance imaging as part of medical evaluation. 5. no contraindication to cardiac magnetic resonance imaging (such as cochlear implants, central nervous system aneurysm clips and other implanted medical devices). 6. age 18 years and older exclusion criteria: 1) insufficient image quality for determination of maximal wall thickness.

Keywords: echocardiography hypertrophic cardiomyopathy cardiomyopathy magnetic resonance imaging contrast
imrt plus cisplatin versus imrt in patients with stage 2 nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma

Summary: nasopharyngeal carcinoma has high incidence in the southern china, especially in guangdong province. in the world, the standardized morbidity has reached 30/10 million in men while in women, about 13/10 million. at present, the incidence of nasopharyngeal carcinoma in china accounted for more than 80% of the world. the cancer-related deaths is in the eighth, which is a serious threat to our people's health and life. a recent multi-center phase ii study of stage ii nasopharyngeal carcinoma showed that: compared with intensity modulation radiotherapy (imrt) plus cisplatin, the 3 year local control rate, regional control rate, distant metastasis-free survival rate and disease-specific survival rate of imrt were similar, but the side effects of radiotherapy alone group were lower. based on the results of the phase ii clinical study, the investigators designed this phase iii clinical study, with the aim to compared the efficacy and toxicity of these two treatment programs. and finally to provide sufficient evidence for the treatment of stage ii nasopharyngeal carcinoma.


Eligibility criteria:
inclusion criteria: * the sex of the subject is not limited, the age is from 18 to 70 years old; * histologically proven nasopharyngeal squamous cell carcinoma, world health organization (who) ii-iii type; * union internationale contre le cancer(uicc) stage 9 clinical stage ii patients； * karnofsky score ≥ 80 points; * no evidence of distant metastasis; * having an nasopharyngeal mri before treatment ,which can measure the size of the tumor in order to analyze the effect. exclusion criteria: * the subject had previously suffered from other malignancies (except non-melanotic skin cancer or cervical carcinoma in situ); * previously received immunotherapy; * previously received chemotherapy; * previously received radiation therapy; * patients who had previously undergone surgical treatment for head and neck tumors (excluding cervical lymphadenectomy); * evidence of distant metastases or other malignancies at the same time.

Keywords: nasopharyngeal carcinoma intensity modulated radiotherapy cisplatin
transhiatal tunnel valvuloplasty for reconstruction following the laparoscopic proximal gastrectomy

Conditions: Gastric Cancer

Summary: patients who meet the inclusion criteria will undergo laparoscopic proximal gastric cancer radical surgery, and esophagogastric anastomosis will be performed using the thtv method. review the surgical video and record the time for making the extracorporeal muscle flap, tunnel passage time, and anastomosis time. the production time of the muscle flap is based on the electric knife incision of the muscle flap as the starting point, and successfully penetrating the muscle flap as the endpoint. the tunnel passes through time, pulling the residual end of the esophagus, and starting to pass through the gastric muscle flap tunnel as the time starting point. the complete placement of the gastric tube into the lower mediastinum is used as the time endpoint. the anastomosis time is calculated from the first needle of suturing the residual stomach and the posterior wall of the esophagus until the end of the plasma flap suturing. record perioperative indicators such as surgical time, bleeding volume, and postoperative hospital stay. the definition of anastomotic stenosis is that in gastroscopy, those who cannot pass through the anastomotic site with ultra-fine endoscopy are judged as anastomotic stenosis. postoperative pathology was performed using the 8th edition ajcc staging. follow up every three months after surgery, including blood tests, liver and kidney function, and tumor markers. according to the situation, choose gastroscopy, upper gastrointestinal imaging, and chest abdominal pelvic enhanced ct. evaluate postoperative reflux symptoms such as heartburn and sternal pain using the visick grading system. gastroscopy los angeles grading was used to evaluate postoperative reflux esophagitis.


Eligibility criteria:
inclusion criteria: 1. confirmed by gastroscopy pathological biopsy and imaging examination as early adenocarcinoma of the upper part of the stomach or adenocarcinoma of the esophageal gastric junction; 2. tumor diameter\<4cm, with no distant metastasis; 3. clinical staging t1-3n0-1m0; 4. on the basis of proximal gastrectomy, 50% of the gastric volume can still be retained; 5. ecog-ps status score 0-1 points (eastern cooperative oncology group). exclusion criteria: 1. patients undergoing preoperative neoadjuvant chemotherapy; 2. patients with severe cardiovascular and pulmonary diseases who cannot tolerate laparoscopic surgery; 3. incomplete clinical data.

Keywords: proximal gastrectomy valvulopathy